Gene-gene interaction of PPARγ and ApoE affects coronary heart disease risk

International Journal of Cardiology

Volumn 92, Issue 2-3, 2003, Pages 257-263

  Peng, Dao Quan ^a   Zhao, Shui Ping ^a   Nie, Sai ^a   Li, Jiang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Apolipoprotein E; CHD; Gene gene interaction; PPAR

Indexed keywords

APOLIPOPROTEIN E4; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ADULT; AGED; ALLELE; AMINO ACID SUBSTITUTION; AMPLIFIED FRAGMENT LENGTH POLYMORPHISM; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CORONARY RISK; FEMALE; GENE INTERACTION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0345097385     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-5273(03)00101-3     Document Type: Article

References (33)

1. Grundy S.M., Pasternak R., Greenland P., et al. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for health professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol. 34:1999;1348-1359.
2. International Task Force for Prevention of Coronary Heart Disease. In cooperation with International Atherosclerosis Society. Coronary heart disease: reducing the risk. 1998.
3. Benes P., Muzik J., Benedik J, et al. Single effects of apolipoprotein B, (a), and E polymorphisms and interaction between plasminogen activator inhibitor-1 and apolipoprotein(a) genotypes and the risk of coronary artery disease in Czech male caucasians. Mol Genet Metab. 69:2000;137-143.
4. Wilson P.W.F., Schaefer E.J., Larson M.G., et al. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis. Arterioscler Thromb Vasc Biol. 16:1996;1250-1255.
5. Peter W.F., Richard H., Martin G., et al. Apolipoprotein E alleles, dyslipidemia and coronary heart disease. J Am Med Assoc. 272:1994;1666-1671.
6. Scuteri A., Bos A.J., Zonderman A.B., et al. Is the apoE4 allele an independent predictor of coronary events? Am J Med. 110:2001;28-32.
7. Vamecq J., Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet. 354:1999;141-148.
8. Kersten S., Desvergne B., Wahli W. Roles of PPARs in health and disease. Nature. 405:2000;421-424.
9. Issemann I., Green S. Activation of a number of the steroid receptor superfamily by peroxisome proliferation. Nature. 374:1990;645-650.
10. Tontonoz P., Nagy L., Alvarez J.G., et al. PPARγ promotes monocytes/macrophage differentiation and uptake of oxidized LDL. Cell. 93:1998;241-252.
11. Ricote M., Huang J., Fajas L., et al. Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA. 95:1998;7614-7619.
12. Jiang C., Ting A.T., Seed B. PPARγ agonists inhibit production of monocyte inflammatory cytokines. Nature. 391:1998;82-86.
13. Ross R. Atherosclerosis-an inflammatory disease. New Engl J Med. 340:1999;115-126.
14. Deeb S.S., Fajas L., Nemoto M., et al. A Pro12Ala substitution in PPARγ2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 20:1998;284-287.
15. Ristow M., Muller-Wieland D., Pfeiffer A., et al. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. New Engl J Med. 339:1998;953-959.
16. Barroso I., Gurnell M., Crowley V.E.F., et al. Dominant negative mutation in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 402:1999;880-883.
17. Wang X.L., et al. Peroxisome proliferator-activator γ C161→T polymorphism and coronary heart disease. Cardiovasc Res. 44:1999;588-594.
18. Hixson J.E., Vernier D.T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 31:1990;545-548.
19. Sheehan D., Bennett T., Cashman K. Apolipoprotein E gene polymorphisms and serum cholesterol in health Irish adults: a proposed genetic marker for coronary artery disease risk. Ir J Med Sci. 169:2000;50-54.
20. Gerdes L.U., Gerdes C., Kervinen K., et al. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction:a substudy of the Scandinavian simvastatin survival study. Circulation. 101:2000;1366-1371.
21. Kardia S.L.R., Haviland M.B., Ferrell R.E., et al. The relationship between risk factor levels and presence of coronary artery calcification is dependent on apolipoprotein E genotype. Arterioscler Thromb Vasc Biol. 19:1999;427-435.
22. Pedersen J.C., Berg K. Gene-gene interaction between the low density lipoprotein receptor and apolipoprotein E loci affects lipid levels. Clin Genet. 38:1990;287-294.
23. Humphries S.E., Talmud P.J., Hawe E., et al. Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet. 358:2001;115-119.
24. Zhu Y., Qi C., Korenberg J.R., et al. Structural organization of mouse peroxisome proliferator-activated receptor γ (mPPAR γ) gene: alternative promoter use and different splicing yield two mPPAR γ isoforms. Proc Natl Acad Sci USA. 92:1995;7921-7925.
25. Beamer B.A., Yen C.J., Anderson R.E., et al. Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-γ2 gene with obesity in two Caucasian populations. Diabetes. 47:1998;1806-1808.
26. Lei H.H., Chen M.H., Yang W.S., et al. Peroxisome proliferator-activated receptor γ 2 Pro 12Ala gene variant is strongly associated with larger body mass in the Taiwanese. Metabolism. 49:2000;1267-1270.
27. Yen C.J., Beamer B.A., Negri C., et al. Molecular scanning of the human peroxisome proliferator activated gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPARγ missense mutation. Biochem Biophys Res Commun. 241:1997;270-274.
28. Koch M., Rett K., Maerker E., et al. The PPARγ2 amino acid polymorphism Pro 12 Ala is prevalent in offspring of type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects. Diabetologia. 42:1999;758-762.
29. Akiyama T.E., Sakai S., Lambert G., et al. Conditional disruption of the peroxisome proliferator-activated receptor γ gene in mice results in lowered expression of ABCA1, ABGA1, and apoE in macrophage and reduced cholesterol efflux. Mol Cell Biol. 22:2002;2607-2619.
30. Vedie B., Jeunemaitre X., Megnien J.L., et al. A new DNA polymorphism in the 5′ untranslated region of the human SREBP-1a is related to development of atherosclerosis in high cardiovascular risk population. Atherosclerosis. 154:2001;589-597.
31. Fajas L., Schoonjans K., Gelman L., et al. Regulation of peroxisome proliferator-activated receptor γ expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism. Mol Cell Biol. 19:1999;5495-5503.
32. Xiang G.D., Xia B.S., Li X.J., et al. Apoε4 allele increase the risk for exercise-induced silent myocardial ischemia in noninsulin-dependent diabetes mellitus. Atherosclerosis. 147:1999;293-296.
33. Meirhaeghe A., Fajas L., Helbecque N., et al. A genetic polymorphism of the peroxisome proliferator-activated receptor γ gene influences plasma leptin levels in obesity humans. Hum Mol Genet. 7:1998;435-440.